• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Medela lays off all in wound division

anonymous

Guest
Entire department cut down to basically a few remote hybrid reps. With some feet on the street “business managers”, former regional managers who were demoted, to visit prospects and handle proposals. Everything will be outsourced to 1099’s from there.